← Markets

DuPont de Nemours, Inc.

DD · NYSE

Market closed$135.29$1.00 (+0.74%)After hours $137.25 · +1.45%

Key statistics

Previous close$134.29
Open$132.92
Day high$135.80
Day low$132.44
52-week high$157.98
52-week low$86.59
Market cap18.27B
Volume941.49K
Average volume1.31M
P/E ratio36.88
Forward P/E13.40
EPS3.67
Dividend yield+1.71%

Market context

Why it moved

DuPont (DD) edged higher as investor interest was supported by its innovation-led strategy and healthcare expansion, even as analysts noted headwinds from weak construction and automotive demand, elevated raw material costs, and ongoing supply disruptions tied to the Middle East conflict.

FortuneZacksStudiooneShautsovaTradingview

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026DuPont de Nemours edged higher, outperforming the broader Basic Materials sector (XLB), as investor attention turns to the company's newly launched Direct Lithium Extraction (DLE) portfolio — a suite of 20+ products targeting the fast-growing lithium production market — and an upcoming Q2 2026 earnings report scheduled for August 4. In after-hours trading, shares extended gains further, rising an additional 1.45%, possibly reflecting bullish analyst sentiment, with Citigroup carrying a $170 price target and Morgan Stanley at $156, well above the current price.

0.7447

July 17, 2026DuPont de Nemours edged down in regular trading and extended its losses in after-hours, as investors weigh the company's newly launched end-to-end Direct Lithium Extraction (DLE) portfolio — spanning 20+ products including sorbents, membranes, and ion exchange resins — against a broader tech-driven market selloff that pressured the materials sector. With Q2 earnings scheduled for August 4 and analyst price targets ranging widely (Citigroup at $170, Morgan Stanley at $156, vs. older targets near $60), attention is building around whether DuPont can validate its post-reverse-split repositioning and reaffirmed full-year adjusted EPS guidance of $7.02–$7.16.

-0.4894

July 16, 2026DuPont de Nemours edged higher, outperforming chemical peer Dow Inc. (which closed down over 2%) as the company garnered investor attention with its launch of an end-to-end Direct Lithium Extraction (DLE) portfolio of more than 20 products — a notable move into the growing critical minerals space. With Q2 earnings scheduled for August 4, analyst sentiment remains constructive, headlined by a bullish $170 price target from Citigroup set earlier this month, well above the current trading level. The broader basic materials sector faced mixed conditions amid geopolitical oil-price pressure from the collapsed U.S.-Iran ceasefire, though a softer-than-expected June CPI reading provided some macro relief for the market.

0.5143

July 14, 2026DuPont closed modestly higher as investors responded to the company's announcement of its Q2 2026 earnings release date (August 4) and a consensus "Moderate Buy" rating from 17 analysts, with an average price target of $165.33 — well above current levels. The stock gained despite a choppy market backdrop shaped by Iran-related geopolitical tensions and a softer-than-expected June CPI print of 3.5%, which helped lift broader equities. DuPont's Q1 EPS beat ($0.55 vs. $0.48 estimate) and FY 2026 guidance of $2.35–$2.40 EPS continue to underpin positive sentiment heading into the next earnings catalyst.

1.1835

July 14, 2026DuPont de Nemours fell roughly 1.5% Monday, underperforming a broadly weak market as a confluence of headwinds weighed on shares. A fresh New York state PFAS lawsuit naming DuPont as a co-defendant alongside 3M continues to shadow the stock — DD dropped 3.7% last week alone on the litigation news — and the overhang persisted into Monday's session. Broader risk-off sentiment driven by renewed U.S.-Iran military tensions and surging oil prices pressured the materials sector (XLB), adding to the drag. Despite a "Moderate Buy" consensus from 17 analysts and an average price target near $165, the stock trades well below that level amid PFAS legal exposure and cyclical sector headwinds.

-1.4999

July 11, 2026DuPont de Nemours closed essentially flat as PFAS litigation headlines weighed on sentiment — the New York Attorney General filed suit against 3M, DuPont, Corteva, and Chemours over toxic 'forever chemicals' in consumer products, a persistent legal overhang for the company. Meanwhile, UBS trimmed its price target modestly to $175 from $177, though 17 analysts maintain a consensus Buy with an average target of ~$171, implying significant upside. Broader context includes DuPont's June 2026 1-for-3 reverse stock split and recent addition to the Russell 1000 Defensive Index, reinforcing its repositioning toward electronics, healthcare, and water solutions ahead of the Qnity spinoff.

-0.0816

July 10, 2026DuPont de Nemours closed lower as a fresh New York Attorney General lawsuit naming the company alongside 3M, Chemours, Corteva, and EIDP over PFAS 'forever chemicals' liability rattled investors, adding to existing litigation overhang. The suit—filed on July 9—seeks corporate liability, environmental remediation funding, and monetary restitution, renewing concerns about DuPont's exposure to regulatory and legal costs even as the company received a modest UBS price target trim to $175 and launched an upgraded WAVE PRO water treatment tool, while broader Basic Materials sentiment was already subdued amid geopolitical-driven macro uncertainty.

-1.5916

July 9, 2026DuPont de Nemours declined nearly 2% amid a broad market risk-off selloff triggered by President Trump declaring the U.S.-Iran ceasefire 'over,' sending oil prices surging and stoking fresh inflation fears. The macro headwinds compounded existing company-specific concerns, as a Seeking Alpha analyst downgraded DD citing persistent macro pressures and the likelihood of weak Q3 guidance ahead of earnings. In after-hours trading, shares slipped an additional 1.4%, while the sector ETF (XLB) held flat after-hours, suggesting DD underperformed peers. On a positive note, DuPont's June 2026 reverse stock split and addition to the Russell 1000 Defensive and Value-Defensive Indexes — alongside billionaire Jeffrey Talpins' backing and a Citi Buy rating with a $170 target — underpin longer-term investor confidence in the company's pivot toward electronics, healthcare, and water solutions.

-1.891

Ad Hoc News · July 17, 2026DuPont stock holds steady as investors await the next catalystInsurance Journal · July 17, 2026New York Sues 3M, DuPont, Other Firms for Funding of PFAS CleanupSimply Wall Street · July 15, 2026DuPont (DD) Launches 20 Product Lithium Extraction Platform For Battery DemandPR Newswire · July 15, 2026DuPont Launches End-to-End Portfolio to Advance Direct Lithium ExtractionAd Hoc News · July 8, 2026DuPont de Nemours Inc updates investors on portfolio and strategy. DD stock reflects ongoing transfoMoomoo · July 2, 2026Mizuho Securities Maintains DuPont(DD.US) With Buy Rating, Maintains Target Price $156Investing.com · June 24, 2026Dupont De Nemours stock reaches all-time high at 140.01 USD24/7 Wall St. · June 22, 2026What Honeywell’s and DuPont’s Coming Reverse Stock Splits Mean for Investors
Mt Newswire · July 9, 20263M, DuPont, Corteva, Chemours Sued by New York AG Over Toxic Pollution From Consumer Products
Benzinga · July 9, 2026New York Attorney General's Suit Names 3M, Chemours, Corteva, DuPont De Nemours; New York Attorney General Sues Chemical Companies Over Alleged Toxic Pollution from Consumer Products
Mt Newswire · July 9, 2026UBS Adjusts Price Target on DuPont de Nemours to $175 From $177
Mt Newswire · July 2, 2026Citigroup Adjusts Price Target on DuPont de Nemours to $170 From $168, Maintains Buy Rating
Mt Newswire · June 25, 2026Goldman Sachs Adjusts Price Target on DuPont de Nemours to $159 From $53, Maintains Neutral Rating
Mt Newswire · June 24, 2026DuPont de Nemours Increased Quarterly Dividend at $0.60, Payable on September 15, to Shareholders of record August 31

Peers

S&P 500SPX · $7,457.78-1.01%Dow Inc.DJI · $29.92+2.12%Eastman Chemical CompanyEMN · $68.60-0.81%PPG Industries, Inc.PPG · $117.36-1.11%Ecolab Inc.ECL · $272.83-1.04%Linde plcLIN · $513.22-1.44%International Flavors & Fragrances Inc.IFF · $78.20+0.77%Honeywell International Inc.HON · $225.02-0.58%3M CompanyMMM · $159.84-1.19%The Sherwin-Williams CompanySHW · $331.32-2.02%Avient CorporationAVNT · $36.97-2.89%Albemarle CorporationALB · $120.78+1.10%